Not meaning to wade into someone else's debate. But does the content of the interim results for Travere's Phase 3 FSGS trial for Sparsentan shed a bit more light on this discussion. I'm expecting something similar from DXB in mid-March. This was almost an identical interim milestone which had a specific proteinuria endpoint and references statistical significance.
Link to their interim results announcement - here
Ann: Application for quotation of securities - DXB, page-112
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.3¢ |
Change
0.008(1.69%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 45.3¢ | 43.0¢ | $174.2K | 396.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1169 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 149763 | 8 |
View Market Depth
| Last trade - 12.29pm 20/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |